Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
PHASE2RecruitingINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
May 15, 2024
Primary Completion Date
April 20, 2026
Study Completion Date
April 20, 2027
Conditions
Hepatocellular Carcinoma
Interventions
DRUG
Cadonilimab
Injectable solution
DRUG
Lenvatinib
capsule
Trial Locations (1)
410013
RECRUITING
Hunan Cancer Hospital, Changsha
All Listed Sponsors
lead
Hunan Cancer Hospital
OTHER
NCT06406634 - Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter